China’s Zai Lab files for $115M Nasdaq IPO to take Tesaro, Bristol-Myers cancer drugs through late-phase trials

Zai Lab has filed to raise up to $115 million in a Nasdaq IPO. The biotech plans to use the money to hustle cancer drugs licensed from Bristol-Myers Squibb and Tesaro through late-phase trials in its home country of China. Since setting up shop in 2014 …
( read original story …)



Related Post